Artelo Biosciences Inc

Artelo Biosciences is a clinical stage company using cutting-edge science to improve patient care.

We were founded in 2017 on the promise of therapeutic development based on lipid-signaling modification, including targeting the receptors of the endocannabinoid system.

Our mission is to alter the course of treatment for those with a diagnosis of cancer and other serious conditions.

At Artelo Biosciences, our scientific research and clinical development are advancing our understanding of how lipid-signaling modification, including targeting the receptors of the endocannabinoid system (ECS), can have an impact in the treatment of cancer and other serious diseases. For cancer and its complications such as cancer anorexia cachexia syndrome, neuropathic pain, anxiety, and sleeplessness, we believe our unique platform may lead to meaningful therapies for patients who currently have few or no treatment options.